Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 52-week single-arm study of subcutaneous mepolizumab in children and adolescents with hypereosinophilic syndrome
MOH_2022-05-09_010099Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in hypereosinophilic syndrome (HES), sponsored by GSK. Started Mar 2022; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on MOH_2022-05-09_010099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-09_010099.